EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer

Ryan Blawski, Bujamin H Vokshi, Xinyu Guo, Srushti Kittane, Mirna Sallaku, Wanlu Chen, Martina Gjyzari, Tony Cheung, Yuhan Zhang, Christopher Simpkins, Weiqiang Zhou, Amanda Kulick und 15 weitere

Cell Reports · 2024

DOI: 10.1016/j.celrep.2024.114174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Ryan Blawski und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Breast Neoplasms, Chromatin. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHGRI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Activating mutations in PIK3CA are frequently found in estrogen-receptor-positive (ER+) breast cancer, and the combination of the phosphatidylinositol 3-kinase (PI3K) inhibitor alpelisib with anti-ER inhibitors is approved for therapy. We have previously demonstrated that the PI3K pathway regulates ER activity through phosphorylation of the chromatin modifier KMT2D. Here, we discovered a methylation site on KMT2D, at K1330 directly adjacent to S1331, catalyzed by the lysine methyltransferase SMYD2. SMYD2 loss attenuates alpelisib-induced KMT2D chromatin binding and alpelisib-mediated changes in gene expression, including ER-dependent transcription. Knockdown or pharmacological inhibition of SMYD2 sensitizes breast cancer cells, patient-derived organoids, and tumors to PI3K/AKT inhibition and endocrine therapy in part through KMT2D K1330 methylation. Together, our findings uncover a regulatory crosstalk between post-translational modifications that fine-tunes KMT2D function at the chromatin. This provides a rationale for the use of SMYD2 inhibitors in combination with PI3Kα/AKT inhibitors in the treatment of ER+/PIK3CA mutant breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone-Lysine N-MethyltransferaseBreast NeoplasmsChromatinHumansFemaleDNA-Binding ProteinsMethylationCell Line, TumorAnimalsMiceProto-Oncogene Proteins c-aktNeoplasm ProteinsReceptors, EstrogenGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

AKTCP: CancerCP: Molecular biologyKMT2DPI3K pathwaySMYD2alpelisibbreast cancerchromatin regulationendocrine therapyestrogen receptor

Substanzen

Histone-Lysine N-MethyltransferaseKMT2D protein, humanSMYD2 protein, humanChromatinDNA-Binding ProteinsProto-Oncogene Proteins c-aktNeoplasm ProteinsReceptors, Estrogen

Autor:innen und Institutionen

  • Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.
  • Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
  • Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD 21205, USA.
  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • AstraZeneca, Waltham, MA 02451, USA.
  • Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Förderung

  • NCI NIH HHS
  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • Breast Cancer Alliance
  • Fund for Innovation in Cancer Informatics
  • National Cancer Institute

Zitieren

APA

Blawski, R., Vokshi, B. H., Guo, X., Kittane, S., Sallaku, M., Chen, W., Gjyzari, M., Cheung, T., Zhang, Y., Simpkins, C., Zhou, W., Kulick, A., Zhao, P., Wei, M., Shivashankar, P., Prioleau, T., Razavi, P., Koche, R., Rebecca, V. W., …, & Toska, E. (2024). Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer. Cell Reports. https://doi.org/10.1016/j.celrep.2024.114174

Vancouver

Blawski R, Vokshi BH, Guo X, Kittane S, Sallaku M, Chen W, et al. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer. Cell Reports. 2024. doi:10.1016/j.celrep.2024.114174

BibTeX
@article{Blawski2024,
  author = {Blawski, Ryan and Vokshi, Bujamin H and Guo, Xinyu and Kittane, Srushti and Sallaku, Mirna and Chen, Wanlu and Gjyzari, Martina and Cheung, Tony and Zhang, Yuhan and Simpkins, Christopher and Zhou, Weiqiang and Kulick, Amanda and Zhao, Peihua and Wei, Meihan and Shivashankar, Pranavkrishna and Prioleau, Tatiana and Razavi, Pedram and Koche, Richard and Rebecca, Vito W and de Stanchina, Elisa and Castel, Pau and Chan, Ho Man and Scaltriti, Maurizio and Cocco, Emiliano and Ji, Hongkai and Luo, Minkui and Toska, Eneda},
  title = {Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer},
  journal = {Cell Reports},
  year = {2024},
  doi = {10.1016/j.celrep.2024.114174}
}
Kostenlos starten →